Johanna Elin Géhin
- Consultant; MD. PhD
- +47 22 93 51 07
Publications 2024
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Rheumatology (Oxford), 63 (6), 1746-1755
DOI 10.1093/rheumatology/kead525, PubMed 37773994
Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis
Clin Exp Rheumatol, 42 (5), 999-1005
DOI 10.55563/clinexprheumatol/ig40gm, PubMed 38197184
Managing hemolysis in serum neuron-specific enolase measurements - an automated algorithm for routine practice
Scand J Clin Lab Invest, 84 (4), 225-229
DOI 10.1080/00365513.2024.2359091, PubMed 38853575
Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients
Front Med (Lausanne), 11, 1461396
DOI 10.3389/fmed.2024.1461396, PubMed 39296891
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
Arthritis Rheumatol, 76 (5), 667-669
DOI 10.1002/art.42764, PubMed 37984460
Publications 2023
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323
Publications 2022
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
BioDrugs, 36 (6), 731-748
DOI 10.1007/s40259-022-00559-1, PubMed 36315391
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002216, PubMed 35980738
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Ann Rheum Dis, 82 (1), 65-73
DOI 10.1136/annrheumdis-2022-222155, PubMed 35551063
Publications 2021
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
Rheumatol Int, 41 (9), 1657-1665
DOI 10.1007/s00296-021-04865-9, PubMed 33944985
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
RMD Open, 7 (3)
DOI 10.1136/rmdopen-2021-001985, PubMed 34911811
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Scand J Rheumatol, 50 (6), 445-454
DOI 10.1080/03009742.2021.1875040, PubMed 33650469
BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
Sci Rep, 11 (1), 11632
DOI 10.1038/s41598-021-91177-4, PubMed 34079038
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077
Publications 2020
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007
Publications 2019
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Arthritis Res Ther, 21 (1), 256
DOI 10.1186/s13075-019-2009-5, PubMed 31783773